<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483248</url>
  </required_header>
  <id_info>
    <org_study_id>SEB-1115-LC</org_study_id>
    <nct_id>NCT01483248</nct_id>
  </id_info>
  <brief_title>Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis</brief_title>
  <official_title>Phase 1/2 Study of Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation for the Evaluation of the Efficacy and Safety in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S-Evans Biosciences Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang General Hospital of Armed Police</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>S-Evans Biosciences Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Orthotopic liver transplantation (OLT) is currently the most effective method for end-stage
      liver diseases. However, the critical shortage of donor organs, high cost, and the problem of
      immune rejection limit its clinical application, and even some patients on the waiting list
      will never survive to receive a matched liver. Stem cell transplantation instead of
      conventional medical therapy or orthotopic liver transplantation will be a promising
      alternate approach to regenerate damaged hepatic mass. Adult mesenchymal stem cells (MSCs)
      are generally thought of as an autologous source of regenerative cells in previous studies.In
      this study, the safety and efficacy of menstrual blood-derived stem cells transplantation for
      patients with liver cirrhosis will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to show whether menstrual blood-derived stem cells can improve
      the disease conditions in patients with liver cirrhosis.

      One of two treatment arms will be assigned to the patients. One group will receive 2 weeks of
      conventional therapy plus MenSCs treatment; The other group will receive 2 weeks of
      conventional therapy plus placebo treatment.

      MenSCs will be cultured and collected in a GMP lab. Patients were strictly monitored after
      the cells injection via i.v.. Patients are followed up at intervals up to at least 2
      years.Clinical parameters such as ascites volume,serum alanine aminotransferase,total
      bilirubin,prothrombin time,albumin,MELD score,and Child-Pugh score will be evaluated at each
      timepoint.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function improvement</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>48 weeks</time_frame>
    <description>such as fever,anaphylaxis,cough,chest distress,and dyspnea,et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement of ascites after 12-week treatment</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MELD score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36-quality of life</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Fibrosis</condition>
  <condition>Liver Disease</condition>
  <condition>Digestive System Disease</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional therapy plus MenSCs treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional therapy plus placebo treatment:
Oral or intravenous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>conventional therapy plus MenSC transplantation</intervention_name>
    <description>patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.
MenSCs transplantation: taken i.v., twice per week, at a dose of 1*10E6 MSC/kg body for 2 weeks.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Interferon</other_name>
    <other_name>Bifendatatum</other_name>
    <other_name>Ursodeoxycholic Acid</other_name>
    <other_name>Menstrual blood-derived stem cells(MenSCs)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional therapy plus placebo treatment</intervention_name>
    <description>25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.</description>
    <arm_group_label>No intervention</arm_group_label>
    <other_name>Interferon</other_name>
    <other_name>Bifendatatum</other_name>
    <other_name>Ursodeoxycholic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Aged 20 to 50years

          -  Liver cirrhosis

          -  Negative pregnancy test

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Malignancies

          -  Sepsis

          -  Vital organs failure

          -  Severe bacteria infection

          -  Vascular thromboses in the portal or hepatic veins
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlie Xiang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>S-Evans Biosciences Co.,Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Zhejiang University-IRB</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://ghr.nlm.nih.gov/</url>
    <description>North American Indian childhood cirrhosis</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>Cirrhosis</description>
  </link>
  <link>
    <url>http://www.fda.gov/</url>
  </link>
  <reference>
    <citation>Houlihan DD, Hopkins LJ, Suresh SX, Armstrong MJ, Newsome PN. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011 Nov;54(5):1891-2; author reply 1892. doi: 10.1002/hep.24722.</citation>
    <PMID>21987440</PMID>
  </reference>
  <reference>
    <citation>Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011 Sep 2;54(3):820-8. doi: 10.1002/hep.24434. Epub 2011 Jul 14.</citation>
    <PMID>21608000</PMID>
  </reference>
  <reference>
    <citation>Forbes SJ, Newsome PN. New horizons for stem cell therapy in liver disease. J Hepatol. 2012 Feb;56(2):496-9. doi: 10.1016/j.jhep.2011.06.022. Epub 2011 Jul 26. Review.</citation>
    <PMID>21798218</PMID>
  </reference>
  <reference>
    <citation>Nikeghbalian S, Pournasr B, Aghdami N, Rasekhi A, Geramizadeh B, Hosseini Asl SM, Ramzi M, Kakaei F, Namiri M, Malekzadeh R, Vosough Dizaj A, Malek-Hosseini SA, Baharvand H. Autologous transplantation of bone marrow-derived mononuclear and CD133(+) cells in patients with decompensated cirrhosis. Arch Iran Med. 2011 Jan;14(1):12-7. doi: 011141/AIM.004.</citation>
    <PMID>21194255</PMID>
  </reference>
  <reference>
    <citation>Zhang D, Jiang M, Miao D. Transplanted human amniotic membrane-derived mesenchymal stem cells ameliorate carbon tetrachloride-induced liver cirrhosis in mouse. PLoS One. 2011 Feb 4;6(2):e16789. doi: 10.1371/journal.pone.0016789.</citation>
    <PMID>21326862</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menstrual blood</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <keyword>Liver cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

